Revenue growth of analgesics in Malaysia 2019-2029

Revenue growth of the analgesics market in Malaysia from 2019 to 2029

Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Supplementary notes

Data provided by Statista Market Insights are estimates.

Definition:
The Analgesics market comprises over-the-counter natural and synthetic non-opioid analgesics (only in approved low doses) like Paracetamol, Ibuprofen, Aspirin, Diclofenac and other pain-relieving preparations. Legislation on opioid analgesics differs from country to country. According to the respective state legislation, legal opioid analgesics are included. In Germany, Austria and Switzerland, for instance, opioid analgesics are only included if they are not limited by the narcotics law and do not require prescription. Analgesics are included in the form of pills, capsules, gels and ointments. Not included are prescription medicines (e.g. morphine), anesthetics and homeopathic remedies. Among the top-selling painkillers are Voltaren, Aspirin, Thomapyrin, Ibuprofen, Dolormin, Paracetamol and ASS. It includes both products which are exclusively sold in pharmacies and products which can be purchased elsewhere. Sales by hospitals are not included.

Additional information:
The Analgesics market comprises revenues, average revenue per capita. Sales channels show online and offline revenue. Revenues include VAT. The market only displays B2C revenues, hence B2B and B2G revenues are not included.
For more information on the data displayed, use the info button next to the boxes.

Citation formats
Use Statista now: unlimited access to all content

Statistics on " Top pharmaceutical drugs "

Other statistics that may interest you Top pharmaceutical drugs

Global overview

3

Top companies' top products

5

Best-selling drugs

8

U.S. overview

6

Outlook

5

Further related statistics

10
Use Statista now: unlimited access to all content
Learn more about how Statista can support your business.